查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2096881

PARP抑制劑藥物治療市場－2026年至2032年全球市場預測

PARP Inhibitors Drug Therapy Market - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 193 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，基於 PARP 抑制劑的藥物療法市場將成長至 151.1 億美元，複合年成長率為 9.88%。

主要市場統計數據
基準年 2025 78億美元
預計年份：2026年 83.3億美元
預測年份 2032 151.1億美元
複合年成長率 (%) 9.88%

PARP抑制劑療法是精準腫瘤學中一項具有重要策略意義的治療手段，因為它靶向具有同源重組缺陷（包括BRCA1和BRCA2突變）的腫瘤中DNA損傷修復的脆弱性。由於獲得了監管部門的批准、基於生物標記的處方以及納入臨床指南，這些療法已在多種癌症治療途徑中得到應用，並在臨床實踐中得到越來越廣泛的應用，尤其是在卵巢、乳癌、前列腺癌和胰腺癌的治療中。其臨床原理可歸結為「合成致死性」。透過抑制聚（ADP-核糖）聚合酵素的活性，癌細胞無法修復單鏈DNA斷裂，進而增加修復缺陷型腫瘤的基因組不穩定性，並促進癌細胞死亡。

目前PARP抑制劑療法的發展現狀受到伴隨診斷應用日益廣泛、維持治療證據不斷積累、免疫查核點抑制劑與抗血管生成藥物聯合治療不斷發展以及對長期安全性的日益重視等因素的影響。產業重點關注的領域包括生物標記檢測基礎設施的建設、治療順序的最佳化、抗藥性管理、患者可及性以及藥物安全性監測。隨著腫瘤治療體係向個人化治療模式轉變，PARP抑制劑的治療策略越來越依賴高品質的分子譜分析、多學科協作的治療決策以及來自不同患者群體的實證醫學證據。

PARP抑制劑現狀的變革性變化

隨著PARP抑制劑的應用範圍從晚期治療擴展到維持治療以及某些固體癌的早期治療，其應用趨勢正在發生變革性轉變。主要腫瘤學體系的臨床指引越來越強調對BRCA突變以及更廣泛的同源重組修復基因進行細胞株和體細胞檢測，從而建構了一個依賴生物標記的治療環境。這項變化正在改變腫瘤科醫師識別合格患者、監測治療結果以及管理不利事件（例如貧血、血小板減少性疾病、疲勞、噁心，以及罕見的臨床嚴重骨髓發育不良症候群症候群和急性骨髓性白血病）的方式。

人工智慧（AI）的累積影響

人工智慧 (AI) 正透過改進腫瘤學相關人員識別患者、解讀分子譜、設計研究以及在實際臨床實踐中管理治療路徑的方式，對基於 PARP 抑制劑的藥物治療產生日益顯著的影響。 AI 驅動的病理學和放射組學工具可以輔助檢測與 DNA 修復缺陷相關的腫瘤表現型，而應用於基因組、轉錄組和臨床資料集的機器學習模型則有助於更精確地評估同源重組缺陷，超越單基因 BRCA 狀態的局限性。這一點尤其重要，因為並非所有 DNA 修復異常對 PARP 抑制劑的反應都相同，抗藥性的產生可能源自於 BRCA 倒位突變、同源重組功能的恢復、藥物外排機制的改變以及複製叉的保護。

PARP抑制劑藥物治療的關鍵區域性見解

由於癌症診斷能力的進步、腫瘤基礎設施的擴建以及基因組檢測在包括中國、日本、韓國、印度和澳洲在內的多個國家得到更廣泛的應用，亞太地區在PARP抑制劑療法方面的重要性日益凸顯。不同地區的法律規範和國家醫保報銷政策差異顯著，這影響著基於生物標記的療法在常規臨床實踐中的普及速度。日本和澳洲擁有完善的臨床指南和伴隨診斷基礎設施，而中國在抗癌藥物核准、國內癌症研究和國內生物標記檢測能力方面正經歷著快速成長。在印度和東南亞部分地區，治療的可近性仍然不穩定，自付費用、專科醫生資源、病理檢測品質以及遺傳諮詢的普及程度等因素都會影響治療的可及性。

東協、海灣合作理事會、歐盟、金磚國家、七國集團和北約的關鍵集團分析

在東南亞國協，隨著新加坡、馬來西亞、泰國、印尼、越南和菲律賓等國癌症診療網路的擴展，基於PARP抑制劑的藥物治療基礎設施正在逐步建立。該地區的進展與BRCA基因和同源重組缺失檢測的普及、訓練有素的遺傳諮詢師的配備、標靶治療納入國家醫療保險報銷體係以及參與國際癌症研究密切相關。新加坡已成為精準醫療的區域中心，而其他東南亞國協則致力於改善診斷基礎設施、規範病理檢測並解決癌症診療資源分配不均的問題。

主要國家PARP抑制劑藥物治療趨勢

美國憑藉其廣泛的法規核准、基於生物標記的治療指南、積極的癌症研究活動以及針對靶向癌症的廣泛細胞株和體細胞檢測，已成為PARP抑製劑治療領域的領先國家。加拿大正透過國家審查流程和省級實施，推動實證醫學的應用，但其可及性受保險報銷標準和檢測途徑的影響。墨西哥主要大都市地區的精準腫瘤學能力正在不斷提升，但公眾獲得分子診斷和標靶治療的機會仍然不均衡。巴西是拉丁美洲該治療領域的領先國家，這得益於不斷成長的癌症專科中心和基因檢測能力，但公立和私立醫療保健之間的差距仍然是一個重大挑戰。

為行業領導者提供的實用建議

產業領導者應優先考慮提高生物標記的質量，具體措施包括加強對檢驗的細胞株和體細胞檢測、同源重組缺陷評估以及遺傳諮詢的普及。成功的PARP抑制劑治療策略需要腫瘤醫療服務提供者、實驗室、保險公司和患者支持系統之間的通力合作，以確保在錯失治療良機前識別出合格的患者。各機構也應加強對臨床醫師的教育投入，重點關注患者選擇、治療順序、抗藥性機制、治療持續時間、劑量管理和長期安全性監測。

調查方法

本執行摘要的調查方法是基於二手研究和來自檢驗的公共來源的證據整合，這些來源包括監管文件、臨床實踐指南、同行評審的腫瘤學文獻、臨床試驗註冊庫、衛生技術評估材料、藥物安全監測資訊以及公開的癌症基因組學和腫瘤學政策資訊來源。本檢驗重點在於PARP抑制劑療法的臨床驗證趨勢，包括已批准的適應症、生物標記要求、安全性考量、區域可及性以及推動醫療保健系統採用的因素。

結論

對於某些DNA修復缺陷型癌症患者而言，PARP抑制劑療法已成為精準腫瘤學的重要支柱。其未來發展取決於對生物標記物更準確的解讀、更早期且更公平的檢測、最佳化的定序、有效的抗藥性管理以及嚴格的長期安全性監測。隨著聯合治療、真實世界數據（REW）的不斷累積以及基因組醫學融入常規癌症治療，PARP抑制劑療法也不斷發展。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 市場動態
  • 波特五力分析
  • PESTLE分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：人工智慧的累積影響，2026年

第7章 PARP抑制劑藥物治療市場：依藥物分類

  • 細香蔥
  • 奧拉帕尼
  • 盧卡帕利
  • 塔拉索帕利

第8章：PARP抑制劑藥物治療市場：依適應症分類

  • 乳癌
  • 卵巢癌
  • 胰臟癌
  • 攝護腺癌

第9章：PARP抑制劑藥物治療市場：依治療類型分類

  • 聯合治療
  • 單藥治療

第10章：PARP抑制劑藥物治療市場：依治療階段分類

  • 一線治療
  • 維持治療
  • 後續治療線

第11章：PARP抑制劑藥物治療市場：依治療領域分類

  • 住院治療
  • 門診

第12章 PARP抑制劑藥物治療市場：依患者年齡層別分類

  • 成人
  • 老年人

第13章：PARP抑制劑藥物治療市場：依最終用戶分類

  • 醫院
  • 零售藥房
  • 專科診所

第14章：PARP抑制劑藥物治療市場：依分銷管道分類

  • 醫院藥房
  • 網路藥房
  • 零售藥房

第15章：PARP抑制劑藥物治療市場：按地區分類

  • 亞太地區
  • 北美洲
  • 拉丁美洲
  • 歐洲
  • 中東
  • 非洲

第16章：PARP抑制劑藥物治療市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第17章 PARP抑制劑藥物治療市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第18章 競爭格局

  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年

第19章：公司簡介

  • AbbVie Inc.
  • Artios Pharma Ltd.
  • AstraZeneca plc
  • Bayer AG
  • BeOne Medicines Ltd.
  • Bristol-Myers Squibb Company
  • Checkpoint Therapeutics, Inc.
  • Clovis Oncology, Inc.
  • Daiichi Sankyo Company, Limited
  • Eisai Co., Ltd.
  • GlaxoSmithKline plc
  • IMPACT Therapeutics
  • JEIL PHARMACEUTICAL CO., LTD.
  • Jiangsu Hengrui Pharmaceuticals Co., Ltd.
  • Johnson & Johnson Services, Inc.
  • Karyopharm Therapeutics Inc.
  • Merck & Co., Inc.
  • Myriad Genetics, Inc.
  • ONO PHARMACEUTICAL CO., LTD.
  • Pfizer Inc.
  • Repare Therapeutics Inc.
  • Ribon Therapeutics, Inc.
  • Takeda Pharmaceutical Company Limited
  • TESARO, Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Zai Lab Limited
Product Code: MRR-AD517FAA716F

The PARP Inhibitors Drug Therapy Market is projected to grow by USD 15.11 billion at a CAGR of 9.88% by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 7.80 billion
Estimated Year [2026] USD 8.33 billion
Forecast Year [2032] USD 15.11 billion
CAGR (%) 9.88%

PARP inhibitors drug therapy has become a strategically important class of precision oncology treatment because it targets DNA damage repair vulnerabilities in tumors with homologous recombination deficiency, including BRCA1 and BRCA2 alterations. These therapies are established across multiple cancer care pathways, most prominently ovarian, breast, prostate, and pancreatic cancers, where regulatory approvals, biomarker-led prescribing, and guideline integration have accelerated clinical adoption. The clinical rationale centers on synthetic lethality: inhibiting poly(ADP-ribose) polymerase activity can prevent cancer cells from repairing single-strand DNA breaks, increasing genomic instability in repair-deficient tumors and supporting tumor cell death.

The PARP inhibitors drug therapy landscape is shaped by expanding companion diagnostic use, growing evidence for maintenance therapy, evolving combinations with immune checkpoint inhibitors and antiangiogenic agents, and intensified attention to long-term safety. Key industry-specific priorities include biomarker testing infrastructure, therapy sequencing, resistance management, patient access, and pharmacovigilance. As oncology systems move toward more personalized treatment models, PARP inhibitor strategies increasingly depend on high-quality molecular profiling, multidisciplinary treatment decisions, and evidence generation across diverse populations.

Transformative Shifts in the PARP Inhibitors Landscape

The PARP inhibitors landscape is undergoing transformative change as use expands from later-line therapy into maintenance and earlier treatment settings across selected solid tumors. Clinical guidelines in major oncology systems increasingly emphasize germline and somatic testing for BRCA alterations and broader homologous recombination repair genes, creating a more biomarker-dependent treatment environment. This shift is changing how oncologists identify eligible patients, monitor treatment benefit, and manage adverse events such as anemia, thrombocytopenia, fatigue, nausea, and rare but clinically serious myelodysplastic syndrome or acute myeloid leukemia.

Another major shift is the movement from single-agent use toward rational combinations. Clinical studies have evaluated PARP inhibitors with immunotherapy, angiogenesis inhibition, hormonal therapy, radiopharmaceuticals, and DNA damage response agents to overcome resistance and broaden response. At the same time, regulatory agencies and clinical experts have become more selective in assessing risk-benefit profiles, especially in recurrent disease settings where overall survival signals, prior lines of therapy, and molecular subgroups influence treatment positioning. The competitive and clinical landscape is therefore transitioning from broad enthusiasm to more disciplined precision use, with emphasis on the right patient, right tumor biology, right treatment duration, and right safety monitoring approach.

Cumulative Impact of Artificial Intelligence

Artificial intelligence is increasingly influencing PARP inhibitors drug therapy by improving how oncology stakeholders identify patients, interpret molecular profiles, design studies, and manage real-world treatment pathways. AI-enabled pathology and radiomics tools can support detection of tumor phenotypes associated with DNA repair deficiency, while machine learning models applied to genomic, transcriptomic, and clinical datasets may help refine homologous recombination deficiency assessment beyond single-gene BRCA status. This is particularly relevant because PARP inhibitor response is not uniform across all DNA repair alterations, and resistance can emerge through BRCA reversion mutations, restoration of homologous recombination, drug efflux changes, and replication fork protection.

In clinical development, AI can support protocol optimization, site selection, eligibility refinement, and identification of underrepresented patient groups for biomarker-driven oncology studies. In care delivery, AI-enabled clinical decision support can help flag patients who require germline counseling, somatic testing, therapy monitoring, or adverse event follow-up. Natural language processing applied to electronic health records can strengthen real-world evidence generation by capturing treatment sequencing, dose modifications, and discontinuation patterns. However, AI deployment must be governed by validated performance, explainability, bias mitigation, privacy safeguards, and alignment with clinical standards. The cumulative impact of AI is therefore not merely operational efficiency; it is the potential to make PARP inhibitor therapy more precise, safer, and more equitable.

Key Regional Insights for PARP Inhibitors Drug Therapy

Asia-Pacific is becoming increasingly important for PARP inhibitors drug therapy because of rising cancer diagnosis capacity, expanding oncology infrastructure, and growing adoption of genomic testing in countries such as China, Japan, South Korea, India, and Australia. Regulatory pathways and national reimbursement decisions differ significantly across the region, shaping how quickly biomarker-guided therapies become available in routine practice. Japan and Australia have well-developed clinical guideline adoption and companion diagnostic infrastructure, while China has rapidly expanded oncology drug approvals, local oncology research, and domestic biomarker testing capacity. India and parts of Southeast Asia continue to face access variability, with out-of-pocket expenditure, specialist availability, pathology quality, and genetic counseling capacity influencing uptake.

North America remains one of the most mature regions for PARP inhibitors drug therapy, supported by established precision oncology guidelines, broad oncology study participation, genetic testing recommendations, and strong integration of germline and somatic testing in breast, ovarian, prostate, and pancreatic cancer pathways. The United States has extensive clinical adoption driven by regulatory approvals and biomarker-based oncology practice, while Canada emphasizes publicly guided reimbursement review and provincial implementation. Europe demonstrates structured adoption through health technology assessment, national oncology guidelines, and strong cancer genomics initiatives across major healthcare systems. Germany, France, Italy, Spain, and the United Kingdom have active precision oncology ecosystems, although reimbursement timelines and molecular testing access vary by country.

Latin America shows growing clinical interest in PARP inhibitors, particularly in Brazil and Mexico, but access is influenced by uneven molecular diagnostics availability, private versus public system differences, and affordability constraints. The Middle East is advancing precision oncology capabilities, especially in Gulf health systems that are investing in tertiary cancer centers, genetic testing, and specialized oncology services. Africa remains highly heterogeneous, with South Africa and select North African settings showing greater oncology infrastructure than many Sub-Saharan settings, where limitations in diagnostics, pathology capacity, specialist access, and treatment funding continue to restrict routine use. Across all regions, the most important determinants of PARP inhibitor adoption are biomarker testing availability, reimbursement, clinician experience, patient selection standards, and post-treatment monitoring systems.

Key Group Insights Across ASEAN, GCC, EU, BRICS, G7, and NATO

ASEAN countries are gradually building capacity for PARP inhibitors drug therapy as oncology networks expand in Singapore, Malaysia, Thailand, Indonesia, Vietnam, and the Philippines. The region's progress is closely tied to access to BRCA and homologous recombination deficiency testing, availability of trained genetic counselors, inclusion of targeted therapies in national reimbursement programs, and participation in multinational oncology studies. Singapore is positioned as a regional precision medicine hub, while other ASEAN systems are working to close gaps in diagnostic infrastructure, pathology standardization, and equitable oncology access.

The GCC has become a notable growth environment for precision oncology because member states are investing in advanced cancer centers, national genomics initiatives, specialist training, and tertiary care capabilities. PARP inhibitor use in GCC settings is supported by increasing availability of molecular diagnostics and referral pathways for hereditary cancer assessment, although long-term access depends on formulary decisions, payer policies, and integration of genetic counseling into routine oncology care. The European Union provides one of the most structured policy environments for PARP inhibitors through centralized drug evaluation, national health technology assessment, cross-border clinical research, and harmonized emphasis on safe, evidence-based use. EU-level oncology initiatives also reinforce the importance of cancer screening, molecular testing, and real-world evidence.

BRICS countries represent a diverse opportunity-and-access landscape. China has rapidly advanced oncology innovation and regulatory review, India is expanding cancer care capacity but faces affordability and diagnostic access barriers, Brazil and South Africa show increasing precision oncology adoption in urban specialty centers, and Russia has oncology infrastructure but access patterns are shaped by national policy and procurement dynamics. G7 countries generally have advanced oncology guidelines, specialist networks, regulatory maturity, and genomic testing capacity, making them important reference systems for therapy sequencing, safety monitoring, and evidence generation. NATO member countries overlap substantially with North American and European oncology systems, where defense alliance status is not clinically relevant but the group includes many countries with mature regulatory institutions, research networks, and healthcare infrastructures that influence access to advanced cancer therapies.

Key Country Insights for PARP Inhibitors Drug Therapy

The United States is a central country for PARP inhibitors drug therapy because of extensive regulatory approvals, biomarker-guided treatment guidelines, oncology research activity, and widespread use of germline and somatic testing in eligible cancers. Canada follows evidence-based adoption through national review processes and provincial implementation, with access shaped by reimbursement criteria and testing pathways. Mexico has growing precision oncology capabilities in major urban centers, although public access to molecular diagnostics and targeted therapy can vary. Brazil is the most prominent Latin American country for this therapy area, supported by specialized cancer centers and increasing genetic testing, while disparities between public and private care remain important.

In Europe, the United Kingdom applies structured health technology assessment and national treatment guidance, with strong integration of genomic medicine into cancer care. Germany benefits from advanced oncology infrastructure, molecular pathology capacity, and specialist-led treatment pathways. France has a long-standing national cancer strategy and organized access to molecular diagnostics, supporting biomarker-led treatment decisions. Italy and Spain have established oncology networks and guideline-based prescribing, though regional reimbursement and testing implementation can differ. Russia has specialist oncology capacity and national treatment programs, but access to advanced targeted therapies depends on regulatory, procurement, and healthcare financing factors.

In Asia-Pacific, China has rapidly expanded cancer drug approvals, local clinical research, and genomic testing capacity, making it a major country for PARP inhibitor adoption in selected cancers. India has a large eligible patient base and expanding oncology centers, but affordability, insurance coverage, and uneven diagnostic access influence practical uptake. Japan has mature regulatory oversight, strong clinical guideline use, and robust companion diagnostic adoption. Australia combines guideline-driven oncology practice with genomic medicine programs and structured reimbursement evaluation. South Korea has advanced cancer care infrastructure, high clinical research intensity, and broad molecular diagnostics capabilities, supporting sophisticated use of PARP inhibitors in appropriate patients. Across all countries, the most consistent success factors are early biomarker testing, clear eligibility criteria, toxicity management, and alignment between diagnostic access and treatment reimbursement.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize biomarker excellence by strengthening access to validated germline and somatic testing, homologous recombination deficiency assessment, and genetic counseling. Successful PARP inhibitor strategies require coordinated partnerships among oncology providers, laboratories, payers, and patient support systems to ensure that eligible patients are identified before treatment windows are missed. Organizations should also invest in clinician education focused on patient selection, treatment sequencing, resistance mechanisms, duration of therapy, dose management, and long-term safety surveillance.

A second priority is evidence generation beyond pivotal studies. Leaders should support real-world evidence programs that evaluate outcomes across diverse populations, including older adults, patients with comorbidities, and underrepresented ethnic groups. Safety monitoring should be embedded into patient pathways, with clear protocols for hematologic surveillance and management of persistent cytopenias. Access strategies should address reimbursement alignment between diagnostic testing and therapy, because targeted treatment adoption is limited when biomarker testing is unavailable or unaffordable. Finally, organizations should responsibly adopt AI-enabled tools for study design, patient identification, and evidence synthesis while ensuring transparency, validation, data privacy, and mitigation of algorithmic bias.

Research Methodology

The research methodology for this executive summary is based on secondary research and evidence synthesis from verified public sources, including regulatory documents, clinical practice guidelines, peer-reviewed oncology literature, clinical study registries, health technology assessment materials, pharmacovigilance communications, and publicly available cancer genomics and oncology policy resources. The analysis emphasizes clinically validated trends in PARP inhibitors drug therapy, including approved indications, biomarker requirements, safety considerations, geographic access patterns, and adoption drivers across healthcare systems.

The methodology excludes market sizing, market share analysis, revenue estimation, and forecasting. Instead, it applies qualitative triangulation across scientific, regulatory, and health system evidence to identify consistent patterns in therapy adoption, regional readiness, diagnostic infrastructure, and treatment pathway evolution. Regional, group, and country insights are interpreted through the lens of oncology care capacity, reimbursement structures, molecular testing access, regulatory maturity, and guideline implementation. This approach supports an evidence-backed, optimized executive perspective without relying on speculative commercial projections.

Conclusion

PARP inhibitors drug therapy is firmly established as a key pillar of precision oncology for selected patients with DNA repair-deficient cancers. Its future impact will depend on more accurate biomarker interpretation, earlier and more equitable testing, optimized sequencing, effective management of resistance, and rigorous long-term safety monitoring. The therapy class continues to evolve through combination strategies, expanded real-world evidence, and increasing integration of genomic medicine into routine cancer care.

Regional and country-level adoption remains uneven, primarily due to differences in diagnostic access, reimbursement, oncology infrastructure, and specialist expertise. Health systems that align molecular testing with timely treatment access are better positioned to deliver the clinical benefits of PARP inhibitors to eligible patients. As artificial intelligence, real-world data, and precision diagnostics mature, stakeholders have an opportunity to improve patient identification, personalize treatment pathways, and strengthen outcomes while maintaining evidence-based and safety-focused use.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. New Revenue Opportunities
  • 3.5. Next-Generation Business Models
  • 3.6. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Market Dynamics
    • 4.3.1. Key Drivers
    • 4.3.2. Key Restraints
    • 4.3.3. Key Opportunities
    • 4.3.4. Key Challenges
  • 4.4. Porter's Five Forces Analysis
  • 4.5. PESTLE Analysis
  • 4.6. Market Outlook
    • 4.6.1. Near-Term Market Outlook (0-2 Years)
    • 4.6.2. Medium-Term Market Outlook (3-5 Years)
    • 4.6.3. Long-Term Market Outlook (5-10 Years)
  • 4.7. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. PARP Inhibitors Drug Therapy Market, by Drug

  • 7.1. Introduction
  • 7.2. Niraparib
  • 7.3. Olaparib
  • 7.4. Rucaparib
  • 7.5. Talazoparib

8. PARP Inhibitors Drug Therapy Market, by Indication

  • 8.1. Introduction
  • 8.2. Breast Cancer
  • 8.3. Ovarian Cancer
  • 8.4. Pancreatic Cancer
  • 8.5. Prostate Cancer

9. PARP Inhibitors Drug Therapy Market, by Therapy Type

  • 9.1. Introduction
  • 9.2. Combination Therapy
  • 9.3. Monotherapy

10. PARP Inhibitors Drug Therapy Market, by Line Of Therapy

  • 10.1. Introduction
  • 10.2. First Line
  • 10.3. Maintenance
  • 10.4. Subsequent Line

11. PARP Inhibitors Drug Therapy Market, by Treatment Setting

  • 11.1. Introduction
  • 11.2. Inpatient
  • 11.3. Outpatient

12. PARP Inhibitors Drug Therapy Market, by Patient Age Group

  • 12.1. Introduction
  • 12.2. Adults
  • 12.3. Elderly

13. PARP Inhibitors Drug Therapy Market, by End User

  • 13.1. Introduction
  • 13.2. Hospitals
  • 13.3. Retail Pharmacies
  • 13.4. Specialty Clinics

14. PARP Inhibitors Drug Therapy Market, by Distribution Channel

  • 14.1. Introduction
  • 14.2. Hospital Pharmacies
  • 14.3. Online Pharmacies
  • 14.4. Retail Pharmacies

15. PARP Inhibitors Drug Therapy Market, by Region

  • 15.1. Asia-Pacific
  • 15.2. North America
  • 15.3. Latin America
  • 15.4. Europe
  • 15.5. Middle East
  • 15.6. Africa

16. PARP Inhibitors Drug Therapy Market, by Group

  • 16.1. ASEAN
  • 16.2. GCC
  • 16.3. European Union
  • 16.4. BRICS
  • 16.5. G7
  • 16.6. NATO

17. PARP Inhibitors Drug Therapy Market, by Country

  • 17.1. United States
  • 17.2. Canada
  • 17.3. Mexico
  • 17.4. Brazil
  • 17.5. United Kingdom
  • 17.6. Germany
  • 17.7. France
  • 17.8. Russia
  • 17.9. Italy
  • 17.10. Spain
  • 17.11. China
  • 17.12. India
  • 17.13. Japan
  • 17.14. Australia
  • 17.15. South Korea

18. Competitive Landscape

  • 18.1. Market Share Analysis, 2025
  • 18.2. FPNV Positioning Matrix, 2025
  • 18.3. Market Concentration Analysis, 2025
    • 18.3.1. Concentration Ratio (CR)
    • 18.3.2. Herfindahl Hirschman Index (HHI)
  • 18.4. Recent Developments & Impact Analysis, 2025
  • 18.5. Product Portfolio Analysis, 2025
  • 18.6. Benchmarking Analysis, 2025

19. Company Profiles

  • 19.1. AbbVie Inc.
  • 19.2. Artios Pharma Ltd.
  • 19.3. AstraZeneca plc
  • 19.4. Bayer AG
  • 19.5. BeOne Medicines Ltd.
  • 19.6. Bristol-Myers Squibb Company
  • 19.7. Checkpoint Therapeutics, Inc.
  • 19.8. Clovis Oncology, Inc.
  • 19.9. Daiichi Sankyo Company, Limited
  • 19.10. Eisai Co., Ltd.
  • 19.11. GlaxoSmithKline plc
  • 19.12. IMPACT Therapeutics
  • 19.13. JEIL PHARMACEUTICAL CO., LTD.
  • 19.14. Jiangsu Hengrui Pharmaceuticals Co., Ltd.
  • 19.15. Johnson & Johnson Services, Inc.
  • 19.16. Karyopharm Therapeutics Inc.
  • 19.17. Merck & Co., Inc.
  • 19.18. Myriad Genetics, Inc.
  • 19.19. ONO PHARMACEUTICAL CO., LTD.
  • 19.20. Pfizer Inc.
  • 19.21. Repare Therapeutics Inc.
  • 19.22. Ribon Therapeutics, Inc.
  • 19.23. Takeda Pharmaceutical Company Limited
  • 19.24. TESARO, Inc.
  • 19.25. Teva Pharmaceutical Industries Ltd.
  • 19.26. Zai Lab Limited

LIST OF FIGURES

  • FIGURE 1. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET, YEARS CONSIDERED FOR THE STUDY
  • FIGURE 2. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET, RESEARCH DESIGN
  • FIGURE 3. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET, RESEARCH FRAMEWORK
  • FIGURE 4. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET, DATA TRIANGULATION
  • FIGURE 5. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 6. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DRUG, 2025 VS 2032 (%)
  • FIGURE 7. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DRUG, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY INDICATION, 2025 VS 2032 (%)
  • FIGURE 9. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY THERAPY TYPE, 2025 VS 2032 (%)
  • FIGURE 11. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY THERAPY TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY LINE OF THERAPY, 2025 VS 2032 (%)
  • FIGURE 13. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY LINE OF THERAPY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY TREATMENT SETTING, 2025 VS 2032 (%)
  • FIGURE 15. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY TREATMENT SETTING, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 16. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2025 VS 2032 (%)
  • FIGURE 17. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 18. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY END USER, 2025 VS 2032 (%)
  • FIGURE 19. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 20. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2032 (%)
  • FIGURE 21. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 22. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY REGION, 2025 VS 2032 (%)
  • FIGURE 23. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 24. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
  • FIGURE 25. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 26. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
  • FIGURE 27. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 28. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 29. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025

LIST OF TABLES

  • TABLE 1. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SEGMENTATION & COVERAGE
  • TABLE 2. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DRUG, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL NIRAPARIB MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL NIRAPARIB MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL NIRAPARIB MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL OLAPARIB MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL OLAPARIB MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL OLAPARIB MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL RUCAPARIB MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL RUCAPARIB MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL RUCAPARIB MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL TALAZOPARIB MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL TALAZOPARIB MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL TALAZOPARIB MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL BREAST CANCER MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL BREAST CANCER MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL BREAST CANCER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL OVARIAN CANCER MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL OVARIAN CANCER MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL OVARIAN CANCER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL PANCREATIC CANCER MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL PANCREATIC CANCER MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL PANCREATIC CANCER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL PROSTATE CANCER MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL PROSTATE CANCER MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL PROSTATE CANCER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL COMBINATION THERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL COMBINATION THERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL COMBINATION THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL MONOTHERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL MONOTHERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL MONOTHERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL FIRST LINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL FIRST LINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL FIRST LINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL MAINTENANCE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL MAINTENANCE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL MAINTENANCE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL SUBSEQUENT LINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL SUBSEQUENT LINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL SUBSEQUENT LINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY TREATMENT SETTING, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL INPATIENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL INPATIENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL INPATIENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL OUTPATIENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL OUTPATIENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL OUTPATIENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL ADULTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL ADULTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL ADULTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL ELDERLY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL ELDERLY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL ELDERLY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL HOSPITALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL HOSPITALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL HOSPITALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL RETAIL PHARMACIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL RETAIL PHARMACIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL RETAIL PHARMACIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL SPECIALTY CLINICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL SPECIALTY CLINICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL SPECIALTY CLINICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL HOSPITAL PHARMACIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL HOSPITAL PHARMACIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL HOSPITAL PHARMACIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL ONLINE PHARMACIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL ONLINE PHARMACIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL ONLINE PHARMACIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL RETAIL PHARMACIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL RETAIL PHARMACIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL RETAIL PHARMACIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 81. ASIA-PACIFIC PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 82. ASIA-PACIFIC PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DRUG, 2018-2032 (USD MILLION)
  • TABLE 83. ASIA-PACIFIC PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 84. ASIA-PACIFIC PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 85. ASIA-PACIFIC PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 86. ASIA-PACIFIC PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY TREATMENT SETTING, 2018-2032 (USD MILLION)
  • TABLE 87. ASIA-PACIFIC PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 88. ASIA-PACIFIC PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 89. ASIA-PACIFIC PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 90. NORTH AMERICA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 91. NORTH AMERICA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DRUG, 2018-2032 (USD MILLION)
  • TABLE 92. NORTH AMERICA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 93. NORTH AMERICA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 94. NORTH AMERICA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 95. NORTH AMERICA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY TREATMENT SETTING, 2018-2032 (USD MILLION)
  • TABLE 96. NORTH AMERICA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 97. NORTH AMERICA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 98. NORTH AMERICA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 99. LATIN AMERICA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 100. LATIN AMERICA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DRUG, 2018-2032 (USD MILLION)
  • TABLE 101. LATIN AMERICA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 102. LATIN AMERICA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 103. LATIN AMERICA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 104. LATIN AMERICA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY TREATMENT SETTING, 2018-2032 (USD MILLION)
  • TABLE 105. LATIN AMERICA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 106. LATIN AMERICA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 107. LATIN AMERICA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 108. EUROPE PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 109. EUROPE PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DRUG, 2018-2032 (USD MILLION)
  • TABLE 110. EUROPE PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 111. EUROPE PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 112. EUROPE PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 113. EUROPE PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY TREATMENT SETTING, 2018-2032 (USD MILLION)
  • TABLE 114. EUROPE PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 115. EUROPE PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 116. EUROPE PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 117. MIDDLE EAST PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 118. MIDDLE EAST PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DRUG, 2018-2032 (USD MILLION)
  • TABLE 119. MIDDLE EAST PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 120. MIDDLE EAST PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 121. MIDDLE EAST PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 122. MIDDLE EAST PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY TREATMENT SETTING, 2018-2032 (USD MILLION)
  • TABLE 123. MIDDLE EAST PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 124. MIDDLE EAST PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 125. MIDDLE EAST PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 126. AFRICA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 127. AFRICA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DRUG, 2018-2032 (USD MILLION)
  • TABLE 128. AFRICA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 129. AFRICA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 130. AFRICA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 131. AFRICA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY TREATMENT SETTING, 2018-2032 (USD MILLION)
  • TABLE 132. AFRICA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 133. AFRICA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 134. AFRICA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 135. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 136. ASEAN PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 137. ASEAN PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DRUG, 2018-2032 (USD MILLION)
  • TABLE 138. ASEAN PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 139. ASEAN PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 140. ASEAN PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 141. ASEAN PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY TREATMENT SETTING, 2018-2032 (USD MILLION)
  • TABLE 142. ASEAN PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 143. ASEAN PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 144. ASEAN PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 145. GCC PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 146. GCC PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DRUG, 2018-2032 (USD MILLION)
  • TABLE 147. GCC PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 148. GCC PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 149. GCC PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 150. GCC PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY TREATMENT SETTING, 2018-2032 (USD MILLION)
  • TABLE 151. GCC PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 152. GCC PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 153. GCC PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 154. EUROPEAN UNION PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 155. EUROPEAN UNION PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DRUG, 2018-2032 (USD MILLION)
  • TABLE 156. EUROPEAN UNION PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 157. EUROPEAN UNION PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 158. EUROPEAN UNION PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 159. EUROPEAN UNION PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY TREATMENT SETTING, 2018-2032 (USD MILLION)
  • TABLE 160. EUROPEAN UNION PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 161. EUROPEAN UNION PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 162. EUROPEAN UNION PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 163. BRICS PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 164. BRICS PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DRUG, 2018-2032 (USD MILLION)
  • TABLE 165. BRICS PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 166. BRICS PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 167. BRICS PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 168. BRICS PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY TREATMENT SETTING, 2018-2032 (USD MILLION)
  • TABLE 169. BRICS PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 170. BRICS PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 171. BRICS PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 172. G7 PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 173. G7 PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DRUG, 2018-2032 (USD MILLION)
  • TABLE 174. G7 PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 175. G7 PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 176. G7 PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 177. G7 PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY TREATMENT SETTING, 2018-2032 (USD MILLION)
  • TABLE 178. G7 PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 179. G7 PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 180. G7 PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 181. NATO PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 182. NATO PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DRUG, 2018-2032 (USD MILLION)
  • TABLE 183. NATO PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 184. NATO PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 185. NATO PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 186. NATO PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY TREATMENT SETTING, 2018-2032 (USD MILLION)
  • TABLE 187. NATO PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 188. NATO PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 189. NATO PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 190. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 191. UNITED STATES PARP INHIBITORS DRUG THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 192. UNITED STATES PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DRUG, 2018-2032 (USD MILLION)
  • TABLE 193. UNITED STATES PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 194. UNITED STATES PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 195. UNITED STATES PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 196. UNITED STATES PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY TREATMENT SETTING, 2018-2032 (USD MILLION)
  • TABLE 197. UNITED STATES PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 198. UNITED STATES PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 199. UNITED STATES PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 200. CANADA PARP INHIBITORS DRUG THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 201. CANADA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DRUG, 2018-2032 (USD MILLION)
  • TABLE 202. CANADA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 203. CANADA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 204. CANADA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 205. CANADA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY TREATMENT SETTING, 2018-2032 (USD MILLION)
  • TABLE 206. CANADA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 207. CANADA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 208. CANADA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 209. MEXICO PARP INHIBITORS DRUG THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 210. MEXICO PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DRUG, 2018-2032 (USD MILLION)
  • TABLE 211. MEXICO PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 212. MEXICO PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 213. MEXICO PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 214. MEXICO PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY TREATMENT SETTING, 2018-2032 (USD MILLION)
  • TABLE 215. MEXICO PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 216. MEXICO PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 217. MEXICO PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 218. BRAZIL PARP INHIBITORS DRUG THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 219. BRAZIL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DRUG, 2018-2032 (USD MILLION)
  • TABLE 220. BRAZIL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 221. BRAZIL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 222. BRAZIL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 223. BRAZIL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY TREATMENT SETTING, 2018-2032 (USD MILLION)
  • TABLE 224. BRAZIL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 225. BRAZIL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 226. BRAZIL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 227. UNITED KINGDOM PARP INHIBITORS DRUG THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 228. UNITED KINGDOM PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DRUG, 2018-2032 (USD MILLION)
  • TABLE 229. UNITED KINGDOM PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 230. UNITED KINGDOM PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 231. UNITED KINGDOM PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 232. UNITED KINGDOM PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY TREATMENT SETTING, 2018-2032 (USD MILLION)
  • TABLE 233. UNITED KINGDOM PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 234. UNITED KINGDOM PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 235. UNITED KINGDOM PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 236. GERMANY PARP INHIBITORS DRUG THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 237. GERMANY PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DRUG, 2018-2032 (USD MILLION)
  • TABLE 238. GERMANY PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 239. GERMANY PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 240. GERMANY PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 241. GERMANY PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY TREATMENT SETTING, 2018-2032 (USD MILLION)
  • TABLE 242. GERMANY PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 243. GERMANY PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 244. GERMANY PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 245. FRANCE PARP INHIBITORS DRUG THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 246. FRANCE PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DRUG, 2018-2032 (USD MILLION)
  • TABLE 247. FRANCE PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 248. FRANCE PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 249. FRANCE PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 250. FRANCE PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY TREATMENT SETTING, 2018-2032 (USD MILLION)
  • TABLE 251. FRANCE PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 252. FRANCE PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 253. FRANCE PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 254. RUSSIA PARP INHIBITORS DRUG THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 255. RUSSIA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DRUG, 2018-2032 (USD MILLION)
  • TABLE 256. RUSSIA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 257. RUSSIA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 258. RUSSIA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 259. RUSSIA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY TREATMENT SETTING, 2018-2032 (USD MILLION)
  • TABLE 260. RUSSIA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 261. RUSSIA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 262. RUSSIA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 263. ITALY PARP INHIBITORS DRUG THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 264. ITALY PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DRUG, 2018-2032 (USD MILLION)
  • TABLE 265. ITALY PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 266. ITALY PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 267. ITALY PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 268. ITALY PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY TREATMENT SETTING, 2018-2032 (USD MILLION)
  • TABLE 269. ITALY PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 270. ITALY PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 271. ITALY PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 272. SPAIN PARP INHIBITORS DRUG THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 273. SPAIN PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DRUG, 2018-2032 (USD MILLION)
  • TABLE 274. SPAIN PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 275. SPAIN PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 276. SPAIN PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 277. SPAIN PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY TREATMENT SETTING, 2018-2032 (USD MILLION)
  • TABLE 278. SPAIN PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 279. SPAIN PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 280. SPAIN PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 281. CHINA PARP INHIBITORS DRUG THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 282. CHINA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DRUG, 2018-2032 (USD MILLION)
  • TABLE 283. CHINA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 284. CHINA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 285. CHINA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 286. CHINA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY TREATMENT SETTING, 2018-2032 (USD MILLION)
  • TABLE 287. CHINA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 288. CHINA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 289. CHINA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 290. INDIA PARP INHIBITORS DRUG THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 291. INDIA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DRUG, 2018-2032 (USD MILLION)
  • TABLE 292. INDIA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 293. INDIA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 294. INDIA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 295. INDIA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY TREATMENT SETTING, 2018-2032 (USD MILLION)
  • TABLE 296. INDIA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 297. INDIA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 298. INDIA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 299. JAPAN PARP INHIBITORS DRUG THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 300. JAPAN PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DRUG, 2018-2032 (USD MILLION)
  • TABLE 301. JAPAN PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 302. JAPAN PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 303. JAPAN PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 304. JAPAN PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY TREATMENT SETTING, 2018-2032 (USD MILLION)
  • TABLE 305. JAPAN PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 306. JAPAN PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 307. JAPAN PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 308. AUSTRALIA PARP INHIBITORS DRUG THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 309. AUSTRALIA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DRUG, 2018-2032 (USD MILLION)
  • TABLE 310. AUSTRALIA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 311. AUSTRALIA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 312. AUSTRALIA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 313. AUSTRALIA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY TREATMENT SETTING, 2018-2032 (USD MILLION)
  • TABLE 314. AUSTRALIA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 315. AUSTRALIA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 316. AUSTRALIA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 317. SOUTH KOREA PARP INHIBITORS DRUG THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 318. SOUTH KOREA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DRUG, 2018-2032 (USD MILLION)
  • TABLE 319. SOUTH KOREA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 320. SOUTH KOREA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 321. SOUTH KOREA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 322. SOUTH KOREA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY TREATMENT SETTING, 2018-2032 (USD MILLION)
  • TABLE 323. SOUTH KOREA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 324. SOUTH KOREA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 325. SOUTH KOREA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 326. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SHARE, BY KEY PLAYER, 2025
  • TABLE 327. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025